GO27834: A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of pinatuzumab vedotin (DCDT2980S) in Combination with Rituximab or Polatuzumab Vedotin (DCDS4501A) in Combination with Rituximab and A Non Randomized phase Ib/II Evaluation of Polatuzumab Vedotin in Combination with Obinutuzumab in Patients with Relapsed or Refractory B-cell Non- Hodgkin’s Lymphoma

Principal Investigator

Andy Chen

Study Purpose

The purpose of this study is to find out the effects, good and/or bad, of two experimental drugs (DCDT2980S or DCDS4501A) have on your cancer. This study involves one of 3 different treatment arms: DCDT2980S plus rituxan, DCDS4501A plus rituxan or DCDS4501A plus obinutuzumab. At this time, the only arm open for enrollment is DCDS4501A plus obinutuzumab. The other arms have completed enrollment.

Medical Condition(s)

Non-Hodgkin's Lymphoma

Eligibility Criteria

Age >17 years old
History of relapsed or refractory Follicular Lymphoma or Diffuse Large B-Cell Lymphoma
Have measurable lesions by CT scan
Never received a prior allogeneic stem cell transplant
No history of transformed disease to Diffuse Large B-Cell Lymphoma
No history of severe allergic reaction to monoclonal antibody therapy (like rituximab)
No history of CNS Lymphoma

Age Range

18 - 99

Healthy Volunteers Needed


Duration of Participation

1 year of treatment; up to 1 additional year of follow-up

Minors Included



Clinical Trials Information Line: Phone 503-494-1080 or


Genentech, Inc

Recruitment End


Compensation Provided


Go Back